Article Text

Download PDFPDF
CASE REPORT
Chemotherapy in combination with stereotactic body radiation therapy (SBRT) for oligometastatic pancreatic cancer
  1. Nikolay Vorobyov1,2,
  2. Ivan Rykov2,3,
  3. Rashida Orlova2,4,
  4. Mikhail Cherkashin5
  1. 1Radiation Oncology, Medical Institute n.a. Berezin Sergey, Saint Petersburg, Russia
  2. 2Oncology, Saint Peterburg State University, Saint-Petersburg, Russia
  3. 3Medical Oncology, Medical Institute n.a. Berezin Sergey, Saint Petersburg, Russia
  4. 4Oncology, Klinicheskaiia bol’nitsa no 122 imeni L G Sokolova, Saint Petersburg, Russia
  5. 5Surgery, Medical Institute n.a. Berezin Sergey, Saint Petersburg, Russia
  1. Correspondence to Dr Mikhail Cherkashin, mikhail.a.cherkashin{at}gmail.com

Summary

Metastatic pancreatic cancer is characterised by poor prognosis. High toxicity of chemotherapy limits its use in elderly patients with severe comorbidities. Meanwhile, in metastatic disease, local treatment did not show the positive effect on life expectancy. We present a clinical case of a 72-year-old woman with metastatic pancreatic adenocarcinoma tumour, node, metastases (T3N0M1) (according to the seventh TNM classification of the International Union Against Cancer). Chemotherapy led to partial response, but later was stopped due to severe toxicity. Thereafter, consolidating radiosurgical treatment was performed. Dose to pancreatic and liver lesions was 35 Gy in five fractions. After 9 months, only one liver lesion and primary pancreatic tumour, stable in size were determined by MRI. At present time, the patient is alive and in good condition, the disease is stable 50 months after stereotactic body radiation therapy (SBRT). SBRT provides a high level of local control and in combination with systemic treatment can potentially increase survival.

  • cancer intervention
  • pancreatic cancer
  • radiotherapy

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Footnotes

  • Contributors NV: concept, design, patient care, writing. IR: patient care, writing. RO: concept, design, editing. MC: writing, editing.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Patient consent Obtained.

  • Provenance and peer review Not commissioned; externally peer reviewed.